drugset / Trial / NCT04028349
ZEBOVAC (Ebola Vaccine Trial, Ad26.ZEBOV/MVA-BN-Filo)
Phase 2
Completed
800 enrolled
MRC/UVRI and LSHTM Uganda Research Unit
Coalition for Epidemic Preparedness Innovations · collabEpicentre, Mbarara, Uganda · collabEpicentre, Paris, France. · collabJanssen Pharmaceutica N.V., Belgium · collab
NaSingle-groupOpen-labelPrevention
Summary
An open-label, single arm phase II study of the candidate Ebola Vaccine Ad26.ZEBOV/MVA-BN®-Filo
Timeline
- Start
- 2019-08-01
- Primary completion
- 2021-03-19
- Completion
- 2021-03-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ad26.ZEBOV/MVA-BN-Filo | Vaccine | — | — |